Patents by Inventor Thomas F. Haws

Thomas F. Haws has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nuclear factor ?B inducing factor
    Patent number: 8642739
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: February 4, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrice Denefle, Thomas F. Haws, June M. Kaplow, Marie Rosier
  • Nuclear factor ?B inducing factor
    Patent number: 8623831
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: January 7, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrice Denefle, Thomas F. Haws, June M. Kaplow, Marie Rosier